Assembly Biosciences (ASMB)
(Delayed Data from NSDQ)
$15.04 USD
-0.09 (-0.59%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $15.00 -0.04 (-0.27%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ASMB 15.04 -0.09(-0.59%)
Will ASMB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ASMB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASMB
Are Medical Stocks Lagging Entera Bio (ENTX) This Year?
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
ASMB: What are Zacks experts saying now?
Zacks Private Portfolio Services
TEVA Shares Rise on Broad Support for Opioids Settlement
After Plunging 17% in 4 Weeks, Here's Why the Trend Might Reverse for Assembly Biosciences (ASMB)
Assembly Biosciences (ASMB) Upgraded to Strong Buy: Here's Why
Other News for ASMB
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
H.C. Wainwright Sticks to Its Hold Rating for Assembly Biosciences (ASMB)
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
Assembly Biosciences doses first participant in Phase 1b trial of ABI-4334
Assembly Biosciences closes $12.6M in equity financings